[5-FU/LV therapy for a rectal cancer patient undergoing continuous hemodialysis with multiple hepatic metastases--a case report].
Chemotherapy for advanced or recurrent colorectal cancer is standardized as oxaliplatin/5-FU/LV therapy (FOLFOX)and irinotecan/5-FU/LV therapy(FOLFIRI). It is difficult to introduce cancer chemotherapy to hemodialysis patients, and limited chemotherapeutics are available. The case was a 57-year-old man who was undergoing continuous hemodialysis when rectal cancer was found with multiple hepatic metastases. After rectum elevation and anterior resection, we treated him with 5-FU/LV therapy. After three courses the number of hepatic metastatic foci decreased, and the ascites disappeared. Levels of carcinoembryonic antigen(CEA)decreased from 837 ng/mL to 29 ng/mL; carbohydrate antigen 19-9(CA19-9)decreased from 79.6 U/mL to 14.2 U/mL, and cancer-related antigen 72-4 (CA72-4)was reduced from 33.3 U/mL to 7.4 U/mL. Partial remission was achieved following the chemotherapy. We used 5-FU/LV therapy according to the Roswell Park Memorial Institute method. Our patient was able to undergo treatment safely without serious adverse drug response, except that he exhibited diarrhea and hand-foot syndrome of grade 2.